Company: QTIWW
Filing Date: 2025-02-05
Form Type: 424B3
Source: 0001628280-25-004061
Chunk: 422

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-02-05
Form: 424B3
Chunk 422
---
 Treasury interest rates whose term in consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and do not anticipate issuing any dividends in the future.

<div align='center'>F-60</div>

#### QT IMAGING HOLDINGS, INC.

### Notes to Condensed Consolidated Financial Statements
<div align='center'>(Unaudited)</div>

The following table shows stock-based compensation expense by functional area in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023:

|                                     |     | 2024 | Three Months Ended 
      September 30, |     | 2023 |         |     | 2024 | Nine months ended 
     September 30, |     | 2023 |         |
|:------------------------------------|:----|:-----|-------------------:|:----|:-----|--------:|:----|:-----|------------------:|:----|:-----|--------:|
| Research and development            |     | $    |             22,248 |     | $    |  26,313 |     | $    |            36,198 |     | $    |  78,941 |
| Selling, general and administrative |     |      |            104,955 |     |      | 169,162 |     |      |           129,989 |     |      | 533,789 |
|                                     |     | $    |            127,203 |     | $    | 195,475 |     | $    |           166,187 |     | $    | 612,730 |

No stock-based compensation expense was capitalized to inventory for three and nine months ended September 30, 2024 and 2023.

As of September 30, 2024, the total unrecognized compensation cost related to all nonvested stock options was $846,533 and the weighted-average period over which it is expected to be recognized is 2.3 years.

#### 13.

#### National Institutes of Health Subaward
On August 18, 2022, the Company was awarded a grant of up to $1,078,347 as a subaward through the Board of Trustees of the University of Illinois for the purpose of developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy. The grant is a cost reimbursement subaward that is allocated